Another emerging cell type is double negative PCa (DNPC)(Group 1, 2→Group 4), which is negative for both AR and neuroendocrine markers and may represent an intermediate phenotype between AR expressing adenocarcinoma and the neuroendocrine phenotype (110). The gene discussed is AR; the disease is posterior cortical atrophy.